Centessa Pharmaceuticals Limited (CNTA) News
Filter CNTA News Items
CNTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CNTA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CNTA News From Around the Web
Below are the latest news stories about CENTESSA PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave is […] |
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical OfficerBOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. “Centessa is ra |
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value EstimateKey Insights Centessa Pharmaceuticals' estimated fair value is US$23.94 based on 2 Stage Free Cash Flow to Equity... |
Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look at where Centessa Pharmaceuticals PLC (NASDAQ:CNTA) stands against the other stocks that jumped yesterday. Broader indices haven’t been performing very well since the Fed’s not so surprise revelation about the number of expected […] |
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturingAn analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals. |
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateAnnounced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three indications ex |
Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesBOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: November 13, 2024Location: Boston, MAFireside Chat: 9:00 AM ET Event: Jefferies London Healthcare Conference Date: Novembe |
Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage BiotechWe recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other small cap stocks with high potential. As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest […] |
Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising DevelopmentsWe recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Centessa Pharmaceuticals Plc (NASDAQ:CNTA) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, […] |
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today shared new preclinical data from non-huma |